McDonald GB, et al. - Given that treatment of hematologic malignancy with antibody-drug conjugates (ADC) may cause liver injury, researchers analyzed patients who received an anti-CD22-calicheamicin conjugate (inotuzumab ozogamicin) to gain insight into mechanisms of sinusoidal injury, as there were no CD22+ cells in the normal liver but non-specific uptake of ADCs by liver sinusoidal endothelial cells. Data reported that the frequencies of sinusoidal obstruction syndrome (SOS) was 1.5% and drug-induced liver injury (DILI) was 7.9% after inotuzumab ozogamicin treatment, compared to none and 1% among controls who received standard chemotherapy. Results of this study suggested that ADCs that do not target antigens present in the normal liver have a relatively low frequency of SOS but a relatively high frequency of DILI.